$GOOGL has an anti-aging asset nobody is pricing. Friedberg @friedberg walked through a Calico paper that should be on Alphabet holders' radar. Calico is Google's longevity lab. Working with Revel Pharma, it used AlphaFold plus directed evolution to design a novel enzyme that degrades CML, the glycation end-product that stiffens tissue and drives aging. The result is not a slide. Across five recursive design cycles the enzyme degraded **52-97%** of CML on human proteins, and on donated skin from patients over 70 it eliminated about **55%** of CML - reversing the skin's profile toward that of a 31-year-old. It is AI-designed proteins doing something genuinely new in biology, not a benchmark score. Chamath @chamath frames the first market as cosmetic: a workable anti-aging cream is a multi-trillion-dollar category. This is the AlphaFold thesis paying out in a product line, and the AlphaFold-to-drugs bridge is exactly what Demis Hassabis @demishassabis has argued is the real near-term return on Google's AI - not chatbots, but designed molecules. Same company, same stack, a second revenue engine the market files under "research." Implication: this is deep-optionality inside a name you already hold on search and cloud. It does not move the $GOOGL model this year. But it is a reminder that Alphabet's AI edge shows up in drug and materials design, an option the Street assigns roughly zero value. If a Calico or Isomorphic asset reaches a real market, that is upside no analyst is underwriting. Watch for Calico or Isomorphic Labs to move a designed molecule toward a commercial or clinical path.